Discoidin Domain Receptor

Discoidin domain receptors (DDRs) are members of the transmembrane receptor tyrosine kinase (RTK) superfamily which are distinguished from others by the presence of a discoidin motif in the extracellular domain and their utilization of collagens as internal ligands. Two types of DDRs, DDR1 and DDR2, have been identified with distinct expression profiles and ligand specificities.

Upon collagen binding, DDRs transduce cellular signaling involved in various cell functions, including cell adhesion, proliferation, differentiation, migration, and matrix homeostasis. Altered DDR function resulting from either mutations or overexpression has been implicated in several types of disease, including atherosclerosis, inflammation, cancer, and tissue fibrosis. DDRs have been considered as novel potential molecular targets for drug discovery and increasing efforts are being devoted to the identification of new small molecule inhibitors targeting the receptors.

Discoidin Domain Receptor Inhibitors

7rh
(DDR1-IN-2)

Cat. No.: HY-U00444

7rh (DDR1-IN-2) is a potent inhibitor of **discoidin domain receptor 1** (**DDR1**), with an IC_{50} of 13.1 nM, and also less potently inhibits DDR2, with an IC_{50} of 203 nM.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

DDR Inhibitor

Cat. No.: HY-W018931

DDR Inhibitor is a potent **discoidin domain receptor (DDR)** inhibitor, with an IC_{50} of 3.3 nM for DDR2, and shows 53% inhibition on DDR1 at 1.5 nM.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

DDR-TRK-1

Cat. No.: HY-100695

DDR-TRK-1 is a selective Discoidin Domain Receptor 1 **(DDR1)** inhibitor, with an IC_{50} value of 9.4 nM. DDR-TRK-1 also inhibits TRK family.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DDR1-IN-1

Cat. No.: HY-13979

DDR1-IN-1 is a potent and selective **DDR1 receptor tyrosine kinase** inhibitor with an IC_{50} of 105 nM; 4-fold less potent for DDR2 (IC_{50} = 413 nM).



Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DDR1-IN-1 dihydrochloride

Cat. No.: HY-13979A

DDR1-IN-1 dihydrochloride is a potent and selective **DDR1 receptor tyrosine kinase** inhibitor with an IC_{50} of 105 nM; 4-fold less potent for DDR2 (IC_{50} = 413 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DDR1-IN-4

Cat. No.: HY-114173

DDR1-IN-4 (Compound 2.45) is a selective and potent **Discoidin Domain Receptor 1 (DDR1)** autophosphorylation inhibitor, with IC_{50} values of 29 nM and 1.9 μM for DDR1 and DDR2, respectively.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DDR1-IN-5

Cat. No.: HY-133669

DDR1-IN-5 is a selective **Discoidin Domain Receptor family, member 1 (DDR1)** inhibitor with an IC_{50} of 7.36 nM. DDR1-IN-5 inhibits auto-phosphorylation DDR1b (Y513) with an IC_{50} of 4.1 nM. DDR1-IN-5 has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DDR1-IN-6

Cat. No.: HY-133670

DDR1-IN-6 is a selective **Discoidin Domain Receptor family, member 1 (DDR1)** inhibitor with an IC_{50} of 9.72 nM. DDR1-IN-6 inhibits auto-phosphorylation DDR1b (Y513) with an IC_{50} of 9.7 nM. DDR1-IN-6 has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DDR2-IN-1

Cat. No.: HY-112545

DDR2-IN-1 is potent **DDR2** inhibitor with an IC_{50} of 26 nM. DDR2-IN-1, compound 129, can be used for osteoarthritis research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR1/DDR2 inhibitor 1

Cat. No.: HY-114311

FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of **fibroblast growth factor receptor 1 (FGFR1)** and **discoindin domain receptor 2 (DDR2)**, with IC_{50} values of 31.1 nM and 3.2 nM, respectively. Antitumor activity.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Merestinib

(LY2801653) Cat. No.: HY-15514

Merestinib (LY2801653) is a potent, orally bioavailable **c-Met** inhibitor (K_i=2 nM) with anti-tumor activities.



Purity: 99.99%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Merestinib dihydrochloride

(LY2801653 dihydrochloride) Cat. No.: HY-15514A

Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable **c-Met** inhibitor (K_i=2 nM) with anti-tumor activities.



Purity: 99.36%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ML786 dihydrochloride

Cat. No.: HY-14979A

ML786 dihydrochloride is a potent and orally bioavailable **Raf** inhibitor, with IC_{50}s of 2.1, 4.2, and 2.5 nM for ^{V600E}**ΔB-Raf**, **wt B-Raf**, and **C-Raf**, respectively. ML786 dihydrochloride also inhibits **Abl-1**, **DDR2**, **EPHA2**, **KDR**, and **RET** (IC_{50}=<0.5, 7.0, 11, 6.2, 0.8 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sitravatinib

(MGCD516; MG-516) Cat. No.: HY-16961

Sitravatinib (MGCD516) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: 99.59%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Sitravatinib malate

(MGCD516 malate; MG-516 malate) Cat. No.: HY-16961A

Sitravatinib malate (MGCD516 malate) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

VU6015929

Cat. No.: HY-135401

VU6015929 is a potent, selective and orally active dual **discoidin domain receptor 1/2 (DDR1/2)** inhibitor with IC_{50}s of 4.67 nM and 7.39 nM, respectively. VU6015929 potently blocks collagen-induced **DDR1** activation and collagen-IV production.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

WRG-28

Cat. No.: HY-114169

WRG-28 is a selective, extracellularly acting **DDR2** allosteric inhibitor with an IC_{50} of 230 nM. WRG-28 uniquely inhibits receptor-ligand interactions via allosteric modulation of the receptor.



Purity: 99.42%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg